AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15540755 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 0
Study 15540755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11401659 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 86
Study 11401659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 9224960 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 10(6) IU/m2 of IFN-beta
Number of subjects: 49
Study 9224960 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 10(6) IU/m2 of IFN-beta
Number of subjects: 49
Study 9224960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 49
Study 8492101 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b therapy for 1 year
Number of subjects: 11
Study 8492101 — intervention group
Group type: COMPARATOR
Intervention: No therapy for 1 year
Number of subjects: 11
Study 6428307 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosoxacin (300 mg oral dose)
Number of subjects: 287
Study 6428307 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (3.5 g) plus Probenecid (1 g)
Number of subjects: 287
Study 6428307 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosoxacin
Number of subjects: 287
Study 6428307 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 287
Study 30817010 — intervention group
Group type: EXPERIMENTAL
Intervention: PNFplus writing
Number of subjects: 250
Study 30817010 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF
Number of subjects: 250
Study 30817010 — intervention group
Group type: EXPERIMENTAL
Intervention: EW
Number of subjects: 250
Study 30817010 — intervention group
Group type: COMPARATOR
Intervention: Attention control feedback
Number of subjects: 250
Study 30201029 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread-embedding acupuncture (TEA)
Number of subjects: 70
Study 30201029 — intervention group
Group type: COMPARATOR
Intervention: Sham thread-embedding acupuncture (STEA)
Number of subjects: 70
Study 27280960 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational website (UTSMed) accessed within 4 months after baseline survey.
Number of subjects: 1236
Study 27280960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to UTSMed).
Number of subjects: 1236
Study 25315665 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week
Number of subjects: 26
Study 25315665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 26
Study 25315665 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 26
Study 22752356 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 12
Study 22752356 — intervention group
Group type: COMPARATOR
Intervention: No propofol infusion
Number of subjects: 12
Study 20131039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gan-Pi regulatory needling (GPRN)
Number of subjects: 90
Study 20131039 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 90
Study 20131039 — intervention group
Group type: COMPARATOR
Intervention: Blank group (untreated)
Number of subjects: 90
Study 17493508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5.0 mg/day (n=70)
Number of subjects: 301
Study 17493508 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10-20 mg/day (n=82)
Number of subjects: 301
Study 17493508 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4-8 mg/day (n=73)
Number of subjects: 301
Study 17493508 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10-20 mg/day (n=76)
Number of subjects: 301
Study 17375736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization (OD) for milk allergy
Number of subjects: 150
Study 17375736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization (OD) for egg allergy
Number of subjects: 150
Study 17375736 — intervention group
Group type: COMPARATOR
Intervention: Avoidance diet (A) for milk allergy
Number of subjects: 150
Study 17375736 — intervention group
Group type: COMPARATOR
Intervention: Avoidance diet (A) for egg allergy
Number of subjects: 150
Study 15037408 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 14
Study 15037408 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg DHEA
Number of subjects: 14
Study 15037408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12903416 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide
Number of subjects: 0
Study 12903416 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline 5 micrograms mL‐1 (group II)
Number of subjects: 60
Study 8958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline 1.66 micrograms mL‐1 (group III)
Number of subjects: 60
Study 8958491 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% plain (group I)
Number of subjects: 60
Study 1484671 — intervention group
Group type: EXPERIMENTAL
Intervention: one‐piece Staar Model AA‐4203 silicone intraocular lens (IOL) implanted through a 3.2‐millimeter incision
Number of subjects: 112
Study 1484671 — intervention group
Group type: COMPARATOR
Intervention: one‐piece polymethylmethacrylate IOL implanted through a 6.0‐millimeter incision
Number of subjects: 112
Study 3883504 — intervention group
Group type: EXPERIMENTAL
Intervention: oral etoposide (VePe-sid) 300 mg/m2 on days 1 and 2 for 6 cycles
Number of subjects: 325
Study 3883504 — intervention group
Group type: EXPERIMENTAL
Intervention: oral etoposide plus cyclophosphamide 300 mg/m2 IV on days 1 and 2 for 6 cycles
Number of subjects: 325
Study 3883504 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 325
Study 3883504 — intervention group
Group type: EXPERIMENTAL
Intervention: oral etoposide
Number of subjects: 325
Study 31415133 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment (3 hours paediatrician + 4 hours dietician)
Number of subjects: 74
Study 31415133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment (35 hours with a multidisciplinary team)
Number of subjects: 74
Study 31415133 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 74
Study 28428892 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation
Number of subjects: 100
Study 28428892 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 25735985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) at 2.4 standard atmosphere, FI O2 = 1.0, for 90 minutes
Number of subjects: 17
Study 25735985 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (ambient pressure, FI O2 = 0.21)
Number of subjects: 17
Study 23303198 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg/day)
Number of subjects: 36
Study 23303198 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (80 mg/day)
Number of subjects: 36
Study 21768063 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing with feedback
Number of subjects: 0
Study 21768063 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing without feedback
Number of subjects: 0
Study 21768063 — intervention group
Group type: COMPARATOR
Intervention: Restudying
Number of subjects: 0
Study 19465426 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 until progression (arm A)
Number of subjects: 63
Study 19465426 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX7 for six cycles, maintenance without oxaliplatin for 12 cycles, and reintroduction of FOLFOX7 (arm B)
Number of subjects: 63
Study 16920847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignan complex (500 mg/d of SDG)
Number of subjects: 22
Study 16920847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-fat muffin without lignan complex)
Number of subjects: 22
Study 12908850 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a (Avonex and Rebif)
Number of subjects: 2819
Study 12908850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif 44 microg three times weekly
Number of subjects: 2819
Study 12908850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2819
Study 12908850 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Number of subjects: 2819
Study 10999649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal GTN therapy (0.6 mg/hour)
Number of subjects: 18
Study 10999649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual GTN (0.6 mg)
Number of subjects: 18
Study 10999649 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubation with 22 nM GTN
Number of subjects: 18
Study 10999649 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubation with 100 microM GTN
Number of subjects: 18
Study 10999649 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (as a control)
Number of subjects: 18
Study 9360173 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual border tracing by two observers or twice by the same observer
Number of subjects: 25
Study 1588488 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV gp 160 antigens for immunization
Number of subjects: 25
Study 1588488 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV gp 160 antigens with or without vaccinia vector
Number of subjects: 25
Study 3903779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone plus 2% fusidic acid
Number of subjects: 81
Study 3903779 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone alone
Number of subjects: 81
Study 31522033 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg daily
Number of subjects: 595
Study 31522033 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib
Number of subjects: 595
Study 31522033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study 30596749 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling intervention (two DVDs delivered three months apart)
Number of subjects: 160
Study 30596749 — intervention group
Group type: COMPARATOR
Intervention: Didactic intervention (one DVD)
Number of subjects: 160
Study 27159952 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 62
Study 25268340 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus infection
Number of subjects: 170
Study 25268340 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV infection
Number of subjects: 170
Study 25268340 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza infection
Number of subjects: 170
Study 25268340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial infection
Number of subjects: 170
Study 25268340 — intervention group
Group type: EXPERIMENTAL
Intervention: hMPV infection
Number of subjects: 170
Study 22892747 — intervention group
Group type: EXPERIMENTAL
Intervention: VPro StreamClean System (VSS)
Number of subjects: 20
Study 22892747 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle irrigation
Number of subjects: 20
Study 20107464 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Home Offerings via the Mealtime Environment (HOME) program
Number of subjects: 44
Study 20107464 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 44
Study 17283363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 235
Study 17283363 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine (FL)
Number of subjects: 235
Study 16115131 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim (10 microg/kg BW per day)
Number of subjects: 501
Study 16115131 — intervention group
Group type: COMPARATOR
Intervention: filgrastim (10 microg/kg BW per day)
Number of subjects: 501
Study 11794192 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted to produce an INR of 1.4 to 2.8)
Number of subjects: 2206
Study 11794192 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg per day)
Number of subjects: 2206
Study 11794192 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2206
Study 11794192 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2206
Study 9893779 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right (BR) device
Number of subjects: 10
Study 9893779 — intervention group
Group type: COMPARATOR
Intervention: Control night (without BR)
Number of subjects: 10
Study 8034071 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 14
Study 8034071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8034071 — intervention group
Group type: COMPARATOR
Intervention: Normal cycling women (control group)
Number of subjects: 14
Study 2661445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitajet
Number of subjects: 6
Study 31231918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 μg/kg (Group A)
Number of subjects: 54
Study 31231918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 μg/kg (Group B)
Number of subjects: 54
Study 28544533 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (pooled)
Number of subjects: 69
Study 28544533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 25294552 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colorectal resection
Number of subjects: 52
Study 25294552 — intervention group
Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 52
Study 23624890 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (QD) oral mesalazine (1.5 to 2.25 g/d)
Number of subjects: 301
Study 23624890 — intervention group
Group type: COMPARATOR
Intervention: Three-times-daily (TID) oral mesalazine
Number of subjects: 301
Study 22067717 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 99
Study 22067717 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine dermis
Number of subjects: 99
Study 22067717 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy
Number of subjects: 99
Study 22067717 — intervention group
Group type: COMPARATOR
Intervention: Composite failure
Number of subjects: 99
Study 22067717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh group
Number of subjects: 99
Study 18095052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissucol/Tisseel fibrin glue
Number of subjects: 325
Study 18095052 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 325
Study 16580905 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g) + Tropisetron (5 mg)
Number of subjects: 26
Study 16580905 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g) + Granisetron (3 mg)
Number of subjects: 26
Study 16580905 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1 g) + Placebo (saline solution)
Number of subjects: 26
Study 12751271 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg bid)
Number of subjects: 47
Study 12751271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg tid)
Number of subjects: 47
Study 12751271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10705174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 750 mg/d
Number of subjects: 20
Study 10705174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9473972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous concurrent visual feedback during practice
Number of subjects: 0
Study 9473972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feedback during acquisition
Number of subjects: 0
Study 9473972 — intervention group
Group type: COMPARATOR
Intervention: No continuous feedback during practice
Number of subjects: 0
Study 8182012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg/day
Number of subjects: 46
Study 8182012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3214945 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg)
Number of subjects: 8
Study 3214945 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg)
Number of subjects: 8
Study 3214945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3214945 — intervention group
Group type: COMPARATOR
Intervention: RU 486 + Dexamethasone
Number of subjects: 8
Study 31102927 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HMD + vestibular rehabilitation protocol
Number of subjects: 47
Study 31102927 — intervention group
Group type: COMPARATOR
Intervention: Vestibular rehabilitation
Number of subjects: 47
Study 29551675 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor 90 mg twice per day for 2 years
Number of subjects: 300
Study 29551675 — intervention group
Group type: COMPARATOR
Intervention: aspirin 81 mg twice per day for 2 years
Number of subjects: 300
Study 26934973 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Engagement of Meaningful Activities (DEMA)
Number of subjects: 36
Study 26934973 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 36
Study 24507460 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (4,000 IU/d)
Number of subjects: 42
Study 24507460 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D3 (600 IU/d)
Number of subjects: 42
Study 23059774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) maintenance therapy after induction with carboplatin and paclitaxel (CP)
Number of subjects: 351
Study 23059774 — intervention group
Group type: COMPARATOR
Intervention: Control group (CP alone)
Number of subjects: 351
Study 19535661 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 153
Study 19535661 — intervention group
Group type: COMPARATOR
Intervention: Individual appointments
Number of subjects: 153
Study 17609910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lirukang Granule (LRKG), 1 package orally thrice a day for 4 months
Number of subjects: 100
Study 17609910 — intervention group
Group type: COMPARATOR
Intervention: Rukuaixiao Tablet, 4 tablets orally thrice a day for 4 months
Number of subjects: 100
Study 17609910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lirukang Granule (LRKG)
Number of subjects: 100
Study 15355137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalignable differences
Number of subjects: 0
Study 15355137 — intervention group
Group type: EXPERIMENTAL
Intervention: Alignable differences
Number of subjects: 0
Study 15355137 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual constraints
Number of subjects: 0
Study 12002519 — intervention group
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS) applied in the morning after PSD for 4 days
Number of subjects: 20
Study 12002519 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 10388228 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNOR counts measured by silver staining method
Number of subjects: 0
Study 10388228 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cadherin expression assessed by immunohistochemistry
Number of subjects: 0
Study 10388228 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between high P AgNOR and decreased E-cadherin expression
Number of subjects: 0
Study 7882099 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) parenterally twice daily for 10 days
Number of subjects: 78
Study 7882099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 2239131 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (rectal solution every 12 hours when temperature is 38.5 degrees C or more)
Number of subjects: 219
Study 2239131 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (suppositories at times of fever)
Number of subjects: 219
Study 2239131 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls from Denmark
Number of subjects: 219
Study 2239131 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 219
Study 2239131 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 219
Study 267565 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkhoff's iodoform paste
Number of subjects: 171
Study 267565 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 171
Study 6787702 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) 6 mg per day
Number of subjects: 16
Study 6787702 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GST)
Number of subjects: 16
Study 31290776 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed PIVC system
Number of subjects: 0
Study 31290776 — intervention group
Group type: COMPARATOR
Intervention: Open PIVC system
Number of subjects: 0
Study 31915550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention on asthma management and proper use of inhalers
Number of subjects: 72
Study 31915550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist intervention)
Number of subjects: 72
Study 31915550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 72
Study 26672998 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based self-management program (8 biweekly meetings of 2.5 hours duration)
Number of subjects: 137
Study 26672998 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 137
Study 26672998 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based self-management program
Number of subjects: 137
Study 25644033 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-acetaminophen
Number of subjects: 70
Study 25644033 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 70
Study 24308613 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. normal saline (20 mL/kg) plus observation
Number of subjects: 144
Study 24308613 — intervention group
Group type: COMPARATOR
Intervention: observation alone
Number of subjects: 144
Study 22049950 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection
Number of subjects: 19